THE FUTURE FOR NEUTRACEUTICALS

8 February 1993

The USA's new Nutrition Labeling and Education Act will not advance the cause of health claims for natural substances, and it maintains the character of the present system, according to Stephen DeFelice, chairman of the Foundation for Innovation in Medicine, which sponsored a conference on a comparison of US, European and Japanese neutraceutical health and medical claims.

Several years ago, Dr DeFelice coined the word "neutraceutical," meaning any substance that can be considered a food or part of a food, and provides medical or health benefits, including the prevention and treatment of disease.

Dr DeFelice suggested that a new system be established for medical and health claims for these natural substances. Once these claims can be made, neutraceuticals will by the year 2000 become a major threat to the food and pharmaceutical industry in the USA. The Europeans and Japanese, already working on these products, will discover and patent these claims, he warned.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight